A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults. PLoS One, 10, e0125954. presented at the 05/2015. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/25961283. (2015).
Assessment of Viral Inhibition Activity in Low Seroprevalent Adenovirus-35 Vectored HIV Vaccines +/- Adjuvanted Protein or Electroporated DNA. In HIV Research for Prevention 2014: AIDS Vaccine, Microbicide and ARV-based Prevention Science (HIVR4P). presented at the 24/09/2014, Cape Town, SA. Retrieved from http://hivr4p.org/. (2014).
Clinical Safety and Immunogenicity of Two HIV Vaccines SeV-G(NP) and Ad35-GRIN in HIV-uninfected, Healthy Adult Volunteers. In HIVR4P (HIV Research for Prevention). presented at the 28/10/2014, Cape Town, South Africa. Retrieved from http://hivr4p.org/. (2014).
Phase 1 Safety and Immunogenicity Evaluation of ADVAX a Multigenic, DNA-Based Clade C/B’ HIV-1 Candidate Vaccine. PLoS ONE, 5, e8617. presented at the 01/2010. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/20111582. (2010).
A Phase 2 Study to Evaluate the Safety and Immunogenicity of a Recombinant HIV Type 1 Vaccine Based on Adeno-Associated Virus. AIDS Res Hum Retroviruses, 26, 933-942. presented at the 08/2010. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/20666584. (2010).
Untitled. presented at the 2004.. (2004).